Advancing treatments for rare diseases together

Caroline Kant

24Nov

In its 24 November 2017 edition, the economic magazine of Bilan devoted a section to philanthropy for research in Switzerland.

EspeRare is featured in an article about the muliple ways to do Philanthropy in the research area. The interview with Caroline Kant, CEO of EspeRare, emphasises the urgency of finding accessible treatments to impact the lives of children with rare diseases. She then explains how the foundation's philanthropic venture model allow to accelerate to fight for rare diseases.

27Feb

For its issue "Special rare diseases", the journal Biotech Finances has chosen to feature EspeRare's CEO, Caroline Kant.The interview summarises Caroline Kant's career path as well as EspeRare's aims, realizations and business plan, thereby informing finance and biotechs specialists of EspeRare's unique business model.

http://www.eei-biotechfinances.com/